Nerviano Medical Sciences
↗Nerviano, Italy
Nerviano Medical Sciences (NMS) is the largest R&D company in Italy dedicated to oncology and a global leader in the discovery and development of innovative cancer therapies. The company operates as the primary research arm of the NMS Group, focusing on the entire value chain from target identification to early clinical development. NMS is renowned for its expertise in kinase inhibitors and its proprietary Antibody-Drug Conjugate (ADC) platform.
Historically part of Farmitalia-Carlo Erba and later Pharmacia/Pfizer, NMS became an independent entity in 2004. Today, it leverages a massive proprietary chemical library and advanced technology platforms to develop first-in-class and best-in-class small molecules. The company has successfully originated several blockbuster drugs, including Entrectinib (Rozlytrek) and Encorafenib (Braftovi), which are now commercialized by global partners.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology Therapeutics & ADCs
SIZE & FINANCIALS
Employees:201-500
Revenue:$40M-$60M
Founded:2004
Ownership:private
Status:operating
FUNDING
Stage:Private Equity
Total Raised:$1.4B+
Investors:PAG (Pacific Alliance Group), Sari (Shanghai Advanced Research Institute), V-Capital
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Small molecule, ADC, Kinase inhibitors
Active Trials:8
Trial Phases:Phase 1: 5 | Phase 2: 3
FDA Approvals:2
EMA Approvals:2
CORPORATE STRUCTURE
Parent Company:NMS Group S.p.A.
Acquired By:PAG (Pacific Alliance Group) (2022-01-01)
Subsidiaries:Nerviano Medical Sciences (Shanghai) Ltd, Nerviano Medical Sciences, Inc. (USA), Accelera (Preclinical CRO)
Key Partnerships:Merck KGaA (Historical NMS-293 partner), Roche/Ignyta (Entrectinib), Pfizer/Pierre Fabre (Encorafenib), Cardiff Oncology (Onvansertib), NovaQuest Capital Management (Royalty financing)
COMPETITION
Position:Leader
Competitors:AstraZeneca, Pfizer, Jazz Pharmaceuticals, Ideaya Biosciences, Artios Pharma
LEADERSHIP
Key Executives:
Hugues Dolgos - CEO
Lisa Mahnke - Chief Medical Officer
Board Members:Andrea Agazzi (Chairman)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Nerviano Medical Sciences. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.